📢 Latest Update:
- Sun Pharmaceutical Industries Ltd, India’s largest revenue-generating drugmaker, has announced the appointment of Kirti Ganorkar as Managing Director effective September 1, 2025 .
- Founder Dilip Shanghvi will transition into the role of Executive Chairman, pending shareholder approval at the AGM scheduled for July 31 .
👨💼 Kirti Ganorkar – Experience & Vision:
- Joined Sun Pharma in 1996 and has led the India business since June 2019, driving consistent market share and revenue growth .
- Played strategic roles in specialty drug launches (including Ilumya), geographic expansion (Japan, Europe), and led multiple functions like marketing, M&A, IP & litigation .
- Holds a chemical engineering degree and an MBA, having undertaken multi-domain leadership within the company.
🌍 North America Leadership Update:
- Abhay Gandhi, CEO for North America and a 30-year veteran, is leaving. He will be succeeded by Richard Ascroft, reporting to COO Aalok Shanghvi .
🔑 Strategic Significance:
- The succession reveals Sun Pharma’s robust internal talent pipeline and structured leadership transition commitment.
- Dilip Shanghvi’s new role will allow focused efforts on expanding the company’s specialty portfolio and long-term innovation direction .
